Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSRF-ADC
- Development stage
- Preclinical
- Lead developer
- Tasrif Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TSRF-ADC is a preclinical-stage antibody-drug conjugate (ADC) being developed by Tasrif Pharmaceutical. It is designed to target the poliovirus receptor (CD155/PVR), a cell surface protein that is frequently overexpressed in various cancers. By binding to CD155, TSRF-ADC is intended to deliver a cytotoxic payload directly to tumor cells, thereby inducing targeted cell death while minimizing systemic toxicity. The specific payload and linker chemistry of TSRF-ADC have not been publicly disclosed.
- Other names
- Anti-CD155 ADCAnti-CD-155 ADCAnti-CD 155 ADC
02
Targets
TOP1 (DNA Topoisomerase I)PVR
Beyond the preview
Go deeper on TSRF-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSRF-ADC.